GENOME WIDE APPROACH TO MELANOMA CLASSIFICATION

$0P50FY2001CANIH

Brigham And Women'S Hospital, Boston MA

Investigators

Linked publications & trials

Paper 29743350 Paper 26993606 Paper 26462027 Paper 26446955 Paper 26415609 Paper 26221190 Paper 26048911 Paper 25787765 Paper 25779945 Paper 25756799 Paper 25637022 Paper 25486484 Paper 25365206 Paper 25319388 Paper 25111691 Paper 25081754 Paper 24978641 Paper 24934811 Paper 24904705 Paper 24850846 Paper 24760312 Paper 24434899 Paper 24431112 Paper 24390216 Paper 24332013 Paper 24300535 Paper 24265154 Paper 24265153 Paper 24185007 Paper 24145241 Paper 24126889 Paper 23785046 Paper 23770371 Paper 23737487 Paper 23563312 Paper 23477830 Paper 23419694 Paper 23416000 Paper 23288408 Paper 23223131 Paper 23171462 Paper 23114601 Paper 23013138 Paper 22980977 Paper 22973452 Paper 22903924 Paper 22869555 Paper 22772464 Paper 22763439 Paper 22718118 Paper 22675174 Paper 22560445 Paper 22545102 Paper 22383798 Paper 22261031 Paper 22184093 Paper 22080950 Paper 21929745 Paper 21801156 Paper 21741599 Paper 21540750 Paper 21445060 Paper 21410764 Paper 21212411 Paper 21160499 Paper 21148332 Paper 21107320 Paper 21085193 Paper 21051013 Paper 21044351 Paper 20977885 Paper 20878214 Paper 20687784 Paper 20679909 Paper 20548315 Paper 20520718 Paper 20484084 Paper 20482672 Paper 20354134 Paper 20233883 Paper 20184545 Paper 20111968 Paper 20068175 Paper 20068151 Paper 20051635 Paper 20042675 Paper 19915144 Paper 19796244 Paper 19751883 Paper 19708024 Paper 19553991 Paper 19516264 Paper 18794336 Paper 18650846 Paper 18560367 Paper 18490728 Paper 18443262 Paper 18370097 Paper 18353142 Paper 18280333

Abstract

DESCRIPTION (provided by applicant): The incidence of malignant melanoma is increasing worldwide at rates that have been reported to be between 3 and 7 percent. In the United States, the incidence of melanoma is rising faster than any other malignancy. The overall goal of this project is to evaluate whether gene expression profiling can provide additional diagnostic and prognostic information for patients with malignant melanoma. Despite decades of attempts to identify clinical and histological features that would be useful in predicting which lesions were going to metastasize, only limited success can be claimed. The measured thickness (the Breslow measurement) and the presence or absence of ulceration are the strongest predictors of outcome for localized disease. The identification of patients with a high risk of metastasis is important for the surgical management of the patient as well as to determine which patients should be admitted to clinical trials of adjuvant agents as these become available. A comprehensive knowledge of the genes expressed by melanoma may be helpful in management of these patients. The specific aims are as follows: 1. To use genome-wide gene expression using microarray technology of human metastatic melanoma and congenital nevi in tissue specimens to identify candidates for accurate prognostication of melanoma patients with localized disease (Stages I and II). 2. Develop in situ hybridization assays for the candidate genes identified in Specific Aim 1. The assays will be validated both on from the tissues used in Specific Aim 1 as well as specimens from additional patients. 3. In situ hybridization will be utilized to examine tissue sections of primary melanomas. The pattern of involvement of the primary tumors will be correlated with clinical outcome. The results will be correlated with known prognostic factors to determine if the information provides additional prognostic information.

View original record on NIH RePORTER →